Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Down 52.9% in May

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totaling 26,663 shares, a decrease of 52.9% from the April 30th total of 56,618 shares. Currently, 0.9% of the shares of the stock are sold short. Based on an average trading volume of 79,808 shares, the short-interest ratio is currently 0.3 days.

Cyclerion Therapeutics Trading Down 2.2%

Shares of Cyclerion Therapeutics stock traded down $0.07 during mid-day trading on Monday, hitting $3.08. 27,087 shares of the stock were exchanged, compared to its average volume of 3,686,895. Cyclerion Therapeutics has a twelve month low of $1.03 and a twelve month high of $8.48. The stock has a market capitalization of $13.34 million, a price-to-earnings ratio of -2.26 and a beta of 1.79. The company has a 50-day simple moving average of $3.03 and a 200 day simple moving average of $1.99.

Cyclerion Therapeutics (NASDAQ:CYCN) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($17.20) by $16.44. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 62.10%. Equities research analysts forecast that Cyclerion Therapeutics will post -1.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Institutional Investors Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.